Relationship among 25-hydroxyvitamin D concentrations, insulin action, and cardiovascular disease risk in patients with essential hypertension

American Journal of Hypertension

Volumn 28, Issue 2, 2015, Pages 266-272

  Abbasi, Fahim ^a   Feldman, David ^a   Caulfield, Michael P ^b   Hantash, Feras M ^b   Reaven, Gerald M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

Blood pressure; Cardiovascular disease; Hypertension; Insulin action; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MULTIVITAMIN; TRIACYLGLYCEROL; 25-HYDROXYVITAMIN D; ANTIHYPERTENSIVE AGENT; GLUCOSE BLOOD LEVEL; VITAMIN D;

25 HYDROXYVITAMIN D BLOOD LEVEL; ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; ESSENTIAL HYPERTENSION; EVALUATION STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; STEADY STATE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN BLOOD LEVEL; ANALOGS AND DERIVATIVES; BLOOD; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HYPERTENSION; MIDDLE AGED; RISK FACTOR; VITAMIN D DEFICIENCY;

ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; RISK FACTORS; TRIGLYCERIDES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84922563837     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpu136     Document Type: Article

References (32)

1. Burgaz A, Orsini N, Larsson SC, Wolk A. Blood 25-hydroxyvitamin D concentration and hypertension: a meta-analysis. J Hypertens 2011; 29:636-645.
2. Kunutsor SK, Apekey TA, Steur M. Vitamin D and risk of future hypertension: meta-analysis of 283, 537 participants. Eur J Epidemiol 2013; 28:205-221.
3. van Ballegooijen AJ, Kestenbaum B, Sachs MC, de Boer IH, Siscovick DS, Hoofnagle AN, Ix JH, Visser M, Brouwer IA. Association of 25-hydroxyvitamin D and parathyroid hormone with incident hypertension: the Multi-Ethnic Study of Atherosclerosis. J Am Coll Cardiol 2014; 63:1214-1222.
4. Zhao G, Ford ES, Li C, Crof JB. Serum 25-hydroxyvitamin D levels and all-cause and cardiovascular disease mortality among US adults with hypertension: the NHANES linked mortality study. J Hypertens 2012; 30:284-289.
5. Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger JR, Li YC, Rodriguez-Iturbe B. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008; 74:1394-1402.
6. Gunta SS, Tadhani RI, Mak RH. The efect of vitamin D status on risk factors for cardiovascular disease. Nat Rev Nephrol 2013; 9:337-347.
7. Krishnan AV, Feldman D. Mechanisms of the anti-cancer and anti-infammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 2011; 51:311-336.
8. Witham MD, Price RJ, Struthers AD, Donnan PT, Messow CM, Ford I, McMurdo ME. Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension: the VitDISH randomized controlled trial. JAMA Intern Med 2013; 173:1672-1679.
9. Witham MD, Nadir MA, Struthers AD. Efect of vitamin D on blood pressure: a systematic review and meta-analysis. J Hypertens 2009; 27:1948-1954.
10. Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K, Lichtenstein AH, Lau J, Balk EM. Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med 2010; 152:307-314.
11. Norman PE, Powell JT. Vitamin D and cardiovascular disease. Circ Res 2014; 114:379-393.
12. Tamez H, Tadhani RI. Vitamin D and hypertension: an update and review. Curr Opin Nephrol Hypertens 2012; 21:492-499.
13. Lima NK, Abbasi F, Lamendola C, Reaven GM. Prevalence of insulin resistance and related risk factors for cardiovascular disease in patients with essential hypertension. Am J Hypertens 2009; 22:106-111.
14. Zavaroni I, Mazza S, Dall'Aglio E, Gasparini P, Passeri M, Reaven GM. Prevalence of hyperinsulinaemia in patients with high blood pressure. J Intern Med 1992; 231:235-240.
15. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Low triglycerides-high high-density lipoprotein cholesterol and risk of ischemic heart disease. Arch Intern Med 2001; 161:361-366.
16. Chen Z, Caulfeld M P, McPhaul MJ, Reitz RE, Taylor S W, Clarke NJ. Quantitative insulin analysis using liquid chromatography-tandem mass spectrometry in a high-throughput clinical laboratory. Clin Chem 2013; 59:1349-1356.
17. Taylor RL, Grebe SK, Singh RJ. Troughput analysis of 25-hydroxyvita-mins D2 and D3 by LC-MS/MS using an automated on-line extraction. Clin Chem 2005; 51:A231-A232.
18. Pei D, Jones CN, Bhargava R, Chen YD, Reaven GM. Evaluation of octreotide to assess insulin-mediated glucose disposal by the insulin suppression test. Diabetologia 1994; 37:843-845.
19. Greenfeld MS, Doberne L, Kraemer F, Tobey T, Reaven G. Assessment of insulin resistance with the insulin suppression test and the euglyce-mic clamp. Diabetes 1981; 30:387-392.
20. Shen S W, Reaven GM, Farquhar J W. Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. J Clin Invest 1970; 49:2151-2160.
21. Knowles J W, Assimes TL, Tsao PS, Natali A, Mari A, Quertermous T, Reaven GM, Abbasi F. Measurement of insulin-mediated glucose uptake: direct comparison of the modifed insulin suppression test and the euglycemic, hyperinsulinemic clamp. Metabolism 2013; 62:548-553.
22. Holick MF, Binkley NC, Bischof-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM, Endocrine S. Evaluation, treatment, and prevention of vitamin D defciency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:1911-1930.
23. Ross AC, Taylor CL, Yaktine AL, Del Valle HB; Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. The National Academies Press: Washington, DC, 2011. ISBN: 978-0-309-16394-1.
24. Sheu WH, Jeng CY, Shieh SM, Fuh MM, Shen DD, Chen YD, Reaven GM. Insulin resistance and abnormal electrocardiograms in patients with high blood pressure. Am J Hypertens 1992; 5:444-448.
25. Heaney RP, French CB, Nguyen S, Ferreira M, Baggerly LL, Brunel L, Veugelers P. A novel approach localizes the association of vitamin D status with insulin resistance to one region of the 25-hydroxyvitamin D continuum. Adv Nutr 2013; 4:303-310.
26. Maestro B, Davila N, Carranza MC, Calle C. Identifcation of a Vitamin D response element in the human insulin receptor gene promoter. J Steroid Biochem Mol Biol 2003; 84:223-230.
27. Dunlop T W, Vaisanen S, Frank C, Molnar F, Sinkkonen L, Carlberg C. The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha, 25-dihydroxyvitamin D3 and its nuclear receptor. J Mol Biol 2005; 349:248-260.
28. Draznin B, Sussman K, Kao M, Lewis D, Sherman N. The existence of an optimal range of cytosolic free calcium for insulin-stimulated glucose transport in rat adipocytes. J Biol Chem 1987; 262:14385-14388.
29. Rao RH. Efects of angiotensin II on insulin sensitivity and fasting glucose metabolism in rats. Am J Hypertens 1994; 7:655-660.
30. Sloniger JA, Saengsirisuwan V, Diehl CJ, Dokken BB, Lailerd N, Lemieux AM, Kim JS, Henriksen EJ. Defective insulin signaling in skeletal muscle of the hypertensive TG(mREN2)27 rat. Am J Physiol Endocrinol Metab 2005; 288:E1074-E1081.
31. Reaven G. Insulin resistance, hypertension, and coronary heart disease. J Clin Hypertens (Greenwich) 2003; 5:269-274.
32. Reaven GM. The insulin resistance syndrome. Curr Atheroscler Rep 2003; 5:364-371.